Evidence map›Paper›PMID 40019916›Full record

ArticlePloS one2025

Acceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study.

Koharu Loulou Chayama, Cara Ng, Isabella Brohman, Manal Mansoor, Will Small, Morgan Philbin, Alexandra B Collins, Ryan McNeil

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Koharu Loulou ChayamaBritish Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
Cara NgBritish Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
Isabella BrohmanBritish Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
Manal MansoorBritish Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0002-2727-3485
Will SmallBritish Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
Morgan PhilbinBenioff Homelessness and Housing Initiative, University of California, San Francisco, San Francisco, California, United States of America.ORCID https://orcid.org/0000-0001-7608-7921
Alexandra B CollinsDepartment of Community Health, School of Arts & Sciences, Tufts University, Medford, Massachusetts, United States of America.
Ryan McNeilBritish Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0003-4452-0764

Funding

Project 4: Neonatal Abstinence Syndrome (NAS): Fetus to First YearsP20GM125507 · NIGMS · RHODE ISLAND HOSPITAL · PI CURT G BECKWITH · 2018 to 2026
$23.4M
The Lifespan/Brown Criminal Justice Research Program on Substance Use and HIVR25DA037190 · NIDA · MIRIAM HOSPITAL · PI CURT G BECKWITH · 2014 to 2026
$3.5M
An ethno-epidemiological study to advance HIV prevention and treatment for PWUDR01DA043408 · NIDA · SIMON FRASER UNIVERSITY · PI MCNEIL, RYAN, SMALL, WILL · 2017 to 2021
$1.7M
NIDA NIH HHS R01 DA043408NIDA NIH HHS R25 DA037190NIGMS NIH HHS P20 GM125507
6 · The paper itself

Abstract

backgroundPeople living with HIV (PLHIV) who use drugs face overlapping social-structural inequities that contribute to suboptimal adherence to antiretroviral therapy (ART). Recent research suggests that long-acting antiretroviral therapy (LA-ART) can offer an important alternative to daily oral ART by mitigating adherence barriers, but this work has largely excluded PLHIV who use drugs. We, therefore, explored the acceptability of injectable and transdermal LA-ART among PLHIV who use drugs in Canada, which has no-cost universal access to oral ART. Greater understanding of PLHIV who use drugs' perspectives on LA-ART will be essential to fully leverage treatment advances and maximize its individual- and population-level benefits.

methodsFrom February 2019 to February 2020, we conducted in-depth interviews with 33 PLHIV who use drugs in Vancouver, Canada with suboptimal ART adherence (i.e., ≦  50%). Participants were recruited for interviews through a prospective cohort study. Interviews were audio-recorded, transcribed, and analyzed using inductive and deductive approaches.

resultsOur analysis identified key factors shaping LA-ART acceptability. First, LA-ART enthusiasm was highest among participants who were less satisfied with oral ART regimens due to pill burden or adverse side effects for oral ART and participants who struggled with daily adherence due substance use and social-structural factors (e.g., homelessness, incarceration). Moreover, participants who had physicians they trusted identified their physicians as credible sources of information on LA-ART, and indicated a desire for informed and shared decision-making regarding treatment changes. Finally, participants emphasized that there is no one-size-fits-all treatment approach for PLHIV who use drugs and highlighted the importance of access to a full range of available treatment options, including LA-ART.

conclusionsThere is potential for high LA-ART uptake among PLHIV who use drugs, particularly those who experience adherence barriers due to their substance use and structural vulnerability. While our findings are limited by the specific population and setting, they nevertheless underscore the need for efforts to ensure universal and equitable access to LA-ART.

Indexed as

Anti-HIV AgentsHIV InfectionsPatient Acceptance of Health CareAdultCanadaFemaleHumansMaleMedication AdherenceMiddle AgedProspective StudiesQualitative ResearchAnti-HIV Agents

Identifiers

PMID40019916
PMCPMC11870339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.